Skybiotech Healt

What does Kapil Cotex do?

Kapil Cotex Ltd is a micro-cap company engaged in the spinning, weaving, and finishing of textiles for the garments industry. As of March 2025, it reported net sales of 1 Cr and a net profit of -1 Cr, with a market cap of Rs 28 Cr.

Overview:<BR>Kapil Cotex Ltd is involved in the spinning, weaving, and finishing of textiles within the garments and apparels industry, categorized as a micro-cap company.<BR><BR>History:<BR>Kapil Cotex Ltd was incorporated on October 14, 1983. In the latest quarter reported, which is March 2025, the company recorded net sales and net profit figures.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 1 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -1 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 28 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 32 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.83 <BR>Return on Equity: -26.36% <BR>Price to Book: 2.94<BR><BR>Contact Details:<BR>Address: UG-276 Dreams The Mall, Gate No 3 LBS Marg Bhandup (W) Mumbai Maharashtra : 400078 <BR>Tel: 91-022-21660432 <BR>Email: kapilcotexlimited@yahoo.co.in <BR>Website: http://www.kapilcotexlimited

Who are in the management team of Kapil Cotex?

As of March 2023, the management team of Kapil Cotex includes Prakashchandra Rathi (Chairman & CFO), Poonam Rathi (Managing Director), Yogesh Nandlal Chandak (Non Executive Director), Jagdish Manohar Mantri (Independent Director), Rakesh Somani (Independent Director), and Swati Maheshwari (Company Secretary & Compliance Officer).

As of March 2023, the management team of Kapil Cotex includes:<BR><BR>1. Prakashchandra Rathi - Chairman & CFO<BR>2. Poonam Rathi - Managing Director<BR>3. Yogesh Nandlal Chandak - Non Executive Director<BR>4. Jagdish Manohar Mantri - Independent Director<BR>5. Rakesh Somani - Independent Director<BR>6. Swati Maheshwari - Company Secretary & Compliance Officer<BR><BR>These individuals play key roles in the governance and management of the company.

Has Kapil Cotex declared dividend?

No Dividend History Available

Is Kapil Cotex overvalued or undervalued?

As of April 25, 2023, Kapil Cotex is considered a risky investment due to its negative financial ratios and poor stock performance, indicating it is overvalued compared to peers in the garments and apparel industry.

As of 25 April 2023, the valuation grade for Kapil Cotex has moved from does not qualify to risky, indicating a significant shift in its perceived investment quality. The company appears to be overvalued based on its financial ratios, which include a PE ratio of -11.70, an EV to EBITDA of -15.57, and a Price to Book Value of 3.08. These negative ratios suggest that the company is struggling to generate profits and is not performing well relative to its asset base.<BR><BR>In comparison with peers, Kapil Cotex's valuation metrics are starkly unfavorable. For instance, Altius Telecom, categorized as very attractive, has a PE ratio of 52.97, while Embassy Office REIT is considered very expensive with a PE ratio of 23.06. The stark contrast in these ratios highlights the challenges faced by Kapil Cotex in the garments and apparel industry. Additionally, the company's recent stock performance has been poor, with a year-to-date return of -47.63% compared to a positive 5.56% return for the Sensex, reinforcing the notion that Kapil Cotex is currently overvalued.

What is the technical trend for Kapil Cotex?

As of May 29, 2025, Kapil Cotex's technical trend has shifted to a moderate bearish stance, driven by bearish signals from the MACD, Bollinger Bands, and moving averages, despite a mildly bullish KST.

As of 29 May 2025, the technical trend for Kapil Cotex has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this include the weekly MACD and Bollinger Bands both indicating bearish conditions, along with daily moving averages also showing a bearish trend. The KST on a weekly basis is mildly bullish, but this is overshadowed by the overall bearish signals from other indicators. The Dow Theory reflects a mildly bearish stance on both weekly and monthly time frames, further supporting the bearish outlook.

Who are the peers of the Kapil Cotex?

Kapil Cotex's peers include STL Global, SVP Global, MKP Mobility, Lakhotia Poly., Sri Ramakr. Mill, High Street Fila, Garment Mantra, Nivaka Fashions, Libas Consumer, and Jakharia Fabric. Performance varies, with High Street Fila showing the highest 1-year return at 190.75% and SVP Global the lowest at -53.09%.

Peers: The peers of Kapil Cotex are STL Global, SVP Global, MKP Mobility, Lakhotia Poly., Sri Ramakr. Mill, High Street Fila, Garment Mantra, Nivaka Fashions, Libas Consumer, and Jakharia Fabric.<BR><BR>Quality Snapshot: Below Average management risk is observed at STL Global, SVP Global, MKP Mobility, Lakhotia Poly., High Street Fila, Nivaka Fashions, and Jakharia Fabric, while Average management risk is found at Sri Ramakr. Mill, Garment Mantra, and Libas Consumer. Growth is rated as Average for MKP Mobility, while Below Average growth is noted for STL Global, SVP Global, Lakhotia Poly., High Street Fila, Nivaka Fashions, and Jakharia Fabric, with Average growth at Sri Ramakr. Mill and Garment Mantra. In terms of Capital Structure, Nivaka Fashions and Libas Consumer have a Good rating, while the rest have Below Average ratings.<BR><BR>Return Snapshot: High Street Fila has the highest 1-year return at 190.75%, while SVP Global has the lowest at -53.09%. Kapil Cotex's 1-year return of 54.86% is significantly higher than SVP Global's but lower than High Street Fila's. Additionally, STL Global, SVP Global, MKP Mobility, and Jakharia Fabric all have negative six-month returns.

Who are the top shareholders of the Kapil Cotex?

The top shareholder of Kapil Cotex is Prakashchandra Rathi, holding 45.16%, with no pledged promoter holdings. The highest public shareholder is Ganesh Shivprasad Lahoti at 4.44%, while individual investors own 33.96% of the shares.

The top shareholders of Kapil Cotex include the promoters, with Prakashchandra Rathi holding the largest share at 45.16%. There are no pledged promoter holdings, and the company does not have any mutual fund or foreign institutional investor (FII) holdings. The highest public shareholder is Ganesh Shivprasad Lahoti, who holds 4.44%. Additionally, individual investors collectively hold 33.96% of the shares.

How big is Kapil Cotex?

As of 22nd July, Kapil Cotex Ltd has a market capitalization of 43.00 Cr and reported Net Sales of 5.14 Cr with a Net Profit loss of 0.48 Cr over the latest four quarters. Shareholder's Funds were 10.83 Cr and Total Assets were 11.53 Cr as of March 2024.

As of 22nd July, Kapil Cotex Ltd has a market capitalization of 43.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 5.14 Cr. However, it faced a loss of 0.48 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2024, where Shareholder's Funds amounted to 10.83 Cr and Total Assets were valued at 11.53 Cr.

How has been the historical performance of Kapil Cotex?

Kapil Cotex experienced significant financial challenges in the fiscal year ending March 2025, reporting net sales of 7.05 Cr but incurring substantial losses with a profit after tax of -2.37 Cr and a net cash outflow of 9.00 Cr, resulting in a closing cash equivalent of 0.00 Cr. Despite increased sales, the company faced rising costs and a decline in profitability compared to the previous year.

Answer:<BR>The historical performance of Kapil Cotex shows significant changes from March 2024 to March 2025.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Kapil Cotex reported net sales of 7.05 Cr, a notable increase from 0.00 Cr in the previous year. However, the total operating income also remained at 7.05 Cr, with raw material costs amounting to 3.67 Cr and total expenditure excluding depreciation rising sharply to 9.31 Cr from just 0.13 Cr. This led to an operating profit (PBDIT) of -1.88 Cr, a decline from a positive 1.87 Cr in March 2024. The company faced a profit before tax of -2.43 Cr, down from 1.88 Cr, resulting in a profit after tax of -2.37 Cr compared to 1.54 Cr the previous year. The earnings per share (EPS) reflected this downturn, falling to -12.34 from 8.02. On the balance sheet, total liabilities stood at 19.18 Cr, with total assets also at 19.18 Cr, indicating a balanced position but with significant debt of 7.20 Cr. The cash flow analysis revealed a net cash outflow of 9.00 Cr, leading to a closing cash equivalent of 0.00 Cr. Overall, the financial results indicate a challenging year for Kapil Cotex, marked by increased sales but substantial losses and cash flow issues.

When is the next results date for Skybiotech Healthcare Limited?

The next results date for Skybiotech Healthcare Limited is 30 May 2026.

The next results date for Skybiotech Healthcare Limited is scheduled for 30 May 2026.

Are Skybiotech Healthcare Limited latest results good or bad?

Skybiotech Healthcare Limited's latest results show mixed signals; while revenue increased significantly by 90.63% quarter-on-quarter, the company still reported a net loss and negative operating margins, indicating ongoing operational challenges and poor profitability. Investors should be cautious due to the negative return on equity and persistent losses.

Skybiotech Healthcare Limited's latest results present a mixed picture, leaning towards the negative. In Q4 FY26, the company reported a net loss of ₹0.30 crores, which is a 37.50% decrease in losses compared to the previous quarter. While this indicates some improvement, the operating margin remains deeply negative at -48.09%, reflecting ongoing operational challenges.<BR><BR>On a more positive note, revenue surged by 90.63% quarter-on-quarter to ₹1.83 crores, showing a significant recovery from the previous quarter's decline. Year-on-year, revenue also increased by 79.41%. However, this revenue growth has not translated into profitability, as the company continues to struggle with converting sales into operating profits.<BR><BR>The return on equity (ROE) is notably negative at -26.36%, indicating poor capital efficiency and value destruction for shareholders. Additionally, the company has faced persistent operational losses over several quarters, raising concerns about its long-term viability.<BR><BR>Overall, while there are signs of revenue recovery, the underlying operational issues and negative profitability metrics suggest that the results are more indicative of ongoing struggles rather than a solid turnaround. Investors should approach with caution, given the company's weak fundamentals and the lack of institutional interest.

Should I buy, sell or hold Skybiotech Healthcare Limited?

Why is Skybiotech Healthcare Limited falling/rising?

As of 03-Jun, the stock price of Skybiotech Healthcare Limited is rising, currently at 157.75, reflecting a change of 2.55 (1.64%) upward. This increase is driven by strong recent performance, heightened investor interest, and positive trading activity.

As of 03-Jun, the stock price of Skybiotech Healthcare Limited is rising, currently at 157.75, reflecting a change of 2.55 (1.64%) upward. This increase can be attributed to several factors. Over the past week, the stock has outperformed the benchmark Sensex, gaining 13.57% compared to the Sensex's decline of 2.01%. Additionally, the stock has shown a strong performance over the last four days, with a cumulative return of 17.31%. <BR><BR>Today, the stock opened with a significant gain of 4.99% and reached an intraday high of Rs 162.95. Furthermore, there has been a notable increase in investor participation, with delivery volume rising by 49.89% against the 5-day average, indicating heightened interest from investors. Despite some erratic trading patterns, where the stock did not trade on one day out of the last twenty, the overall trend suggests a positive momentum for the stock. <BR><BR>In summary, the combination of strong recent performance, increased investor interest, and positive trading activity contributes to the rising stock price of Skybiotech Healthcare Limited.

Which are the latest news on Skybiotech Healt?